Nearly 12 Million Rohto Eye Drops Recalled. The Risk Level Is Where It Gets Complicated.
Nearly 12 million cartons of Rohto Cooling Eye Drops have been pulled from shelves nationwide after the FDA flagged a manufacturing problem at the Vietnam facility where they are made. The recall, initiated voluntarily by Rohto-Mentholatum, covers 11,960,623 cartons across eight product varieties — including All-In-One, Max Strength, Optic Glow, Digi Eye, Dry Aid, and Cool Relief — sold in single and twin-pack formats. Affected bottles carry expiration dates running as far out as February 2029. The distributor is The Mentholatum Company, headquartered in Orchard Park, New York.
That's the story most outlets ran with. Here's the part that quietly changes the conversation:
The FDA did not classify this as its most serious category of recall.
What's not in dispute: the agency cited a "lack of assurance of sterility," meaning the products cannot be confirmed free of potentially harmful microorganisms. Consumers with affected lot numbers are advised to stop using them immediately and either discard the bottles or return them for a full refund.
What is in dispute: whether a Class II designation — the FDA's middle tier, reserved for products that may cause temporary or reversible health effects but are unlikely to produce serious consequences — reflects an appropriate level of regulatory urgency for a product applied directly to the eye.
On one side, the Class II classification is the system working exactly as designed. The recall was voluntary, the company moved quickly, and the FDA's tiered framework exists precisely to distinguish between products that could kill you and products that carry a lower, manageable risk. Nearly 12 million units being pulled before a single confirmed serious injury is, by that read, a success story for the existing framework.
On the other, critics of the current OTC oversight model argue that the eye is not a forgiving target. Unlike a skin cream or a supplement, eye drops bypass the body's most exposed and infection-vulnerable surface. A sterility failure in that context, even one deemed unlikely to cause serious harm, points to a gap between how the FDA categorizes risk and how patients actually experience it. This recall also follows a separate Class II action involving more than 2.5 million bottles of a prescription steroid eye medication pulled over foreign material found in certain lots — suggesting the eye drop supply chain has had a rough stretch.
Which leaves the question that actually matters, and the one no risk classification can answer for you:
Is the FDA's current approach to over-the-counter eye drops — relying on voluntary recalls and after-the-fact enforcement — a reasonable balance between market access and consumer safety, or is it a system that keeps setting the bar just low enough to miss the point?
The whole field is split on it. We dropped the question into the Arena and let the models argue it out. Watch below.
Should the FDA adopt more aggressive pre-market sterility standards for over-the-counter eye drops, or is the current voluntary recall system sufficient?
Listen to the full debate ►The bottleneck argument also conflates stringency with slowness — rigorous pre-market sterility validation of manufacturing processes, not product-by-product testing, would set a higher floor for entry without grinding access to a halt. 🔬 When one company has triggered sterility concerns twice under the current framework and still reached consumers, the framework isn't catching failures early enough — it's documenting them.